195 related articles for article (PubMed ID: 35364770)
1. Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab.
Mimori M; Komatsu T; Maku T; Mitsumura H; Iguchi Y
Neurol Sci; 2022 Jul; 43(7):4081-4083. PubMed ID: 35364770
[TBL] [Abstract][Full Text] [Related]
2. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
Uzawa A; Kuwabara S
Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.
Murai H; Uzawa A; Suzuki Y; Imai T; Shiraishi H; Suzuki H; Okumura M; O'Brien F; Wang JJ; Fujita KP; Utsugisawa K;
J Neurol Sci; 2019 Dec; 407():116419. PubMed ID: 31698177
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
Jiao L; Li H; Guo S
J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
[TBL] [Abstract][Full Text] [Related]
5. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Nowak RJ; Andersen H; Casasnovas C; de Bleecker JL; Vu TH; Mantegazza R; O'Brien FL; Wang JJ; Fujita KP; Howard JF;
Muscle Nerve; 2019 Jul; 60(1):14-24. PubMed ID: 30767274
[TBL] [Abstract][Full Text] [Related]
7. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab: A Review in Generalized Myasthenia Gravis.
Dhillon S
Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
[TBL] [Abstract][Full Text] [Related]
9. Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.
Ohnari K; Hashimoto T; Iwanaka Y; Ohnari K; Adachi H; Okada K
J Neurol; 2024 May; 271(5):2902-2905. PubMed ID: 38393426
[No Abstract] [Full Text] [Related]
10. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis.
Xiao H; Wu K; Liang X; Li R; Lai KP
Front Immunol; 2021; 12():715036. PubMed ID: 34456922
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab for the treatment of myasthenia gravis.
Mantegazza R; Cavalcante P
Expert Opin Biol Ther; 2020 Sep; 20(9):991-998. PubMed ID: 32602752
[TBL] [Abstract][Full Text] [Related]
12. Consistent improvement with eculizumab across muscle groups in myasthenia gravis.
Mantegazza R; O'Brien FL; Yountz M; Howard JF;
Ann Clin Transl Neurol; 2020 Aug; 7(8):1327-1339. PubMed ID: 32700461
[TBL] [Abstract][Full Text] [Related]
13. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
Greenwood GT; Lynch Z
Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
[TBL] [Abstract][Full Text] [Related]
14. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
Datta S; Singh S; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
[TBL] [Abstract][Full Text] [Related]
16. Starting eculizumab as rescue therapy in refractory myasthenic crisis.
Vinciguerra C; Bevilacqua L; Toriello A; Iovino A; Piscosquito G; Calicchio G; Barone P
Neurol Sci; 2023 Oct; 44(10):3707-3709. PubMed ID: 37306795
[TBL] [Abstract][Full Text] [Related]
17. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
18. Temporal correlation between serum CH
Yanagidaira M; Nishida Y; Yokota T
Clin Neurol Neurosurg; 2020 Feb; 189():105630. PubMed ID: 31830679
[TBL] [Abstract][Full Text] [Related]
19. A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment.
Alis C; Emre DH; Karaali Savrun F; Gunduz A; Uzun Adatepe N
Neurol Sci; 2022 Sep; 43(9):5185-5187. PubMed ID: 35525875
[No Abstract] [Full Text] [Related]
20. Eculizumab in refractory myasthenic crisis.
Yeo CJJ; Pleitez MY
Muscle Nerve; 2018 Aug; 58(2):E13-E15. PubMed ID: 29524335
[No Abstract] [Full Text] [Related]
[Next] [New Search]
